$ENTX

Entera Bio Ltd.

CIK:0001638097|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 42
COST OF REVENUES	0	0	0	42
GROSS PROFIT	0	0	0	0
OPERATING EXPENSES:
Research and development, net	3,201	1,520	5,452	2,643
General and administrative	1,362	1,148	2,650	2,588
TOTAL OPERATING EXPENSES	4,563	2,668	8,102	5,231
OPERATING LOSS	4,563	2,668	8,102	5,231
FINANCIAL EXPENSES (INCOME), NET	2,749	(12)	2,715	(8)
Segment net loss	$ 7,312	$ 2,656	$ 10,817	$ 5,223
LOSS PER SHARE BASIC	$ 0.14	$ 0.06	$ 0.22	$ 0.12
LOSS PER SHARE DILUTED	$ 0.14	$ 0.06	$ 0.22	$ 0.12
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE	50,451,232	46,836,700	49,098,428	45,146,415
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE	50,451,232	46,836,700	49,098,428	45,146,415

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,817)	$ (5,223)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	16	15
Share-based compensation	1,296	1,113
Finance expenses, net	18	18
Changes in fair value of pre-funded warrants Liability	2,755	0
Issuance cost	116	0
Changes in operating asset and liabilities:
Increase in other current assets	(48)	(252)
Decrease in accounts receivable	0	126
Increase in accounts payable	127	251
Increase (decrease) in accrued expenses and other payables and other long-term liabilities	(17)	917
Net cash used in operating activities	(6,554)	(3,035)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(3)	(37)
Net cash used in investing activities	(3)	(37)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Ordinary Shares, warrants and pre-funded warrants	10,000	0
Proceeds from issuance of Ordinary Shares under ATM program	0	6,183
Issuance cost	(171)	(261)
Issuance of ordinary shares, under collaboration agreement	0	7,190
Exercise of warrants and options to Ordinary Shares	260	174
Net cash provided by financing activities	10,089	13,286
INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND DEPOSITS	3,532	10,214
EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS	21	0
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND DEPOSITS AT BEGINNING OF THE PERIOD	14,973	8,740
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND DEPOSITS AT END OF THE PERIOD	18,526	18,954
Reconciliation in amounts on consolidated balance sheets:
Cash and cash equivalents	11,309	10,858
Restricted cash and deposits	7,217	8,096
Total cash and cash equivalents and restricted cash and deposit	18,526	18,954
SUPPLEMENTAL DISCLOSURE OF CASH FLOW TRANSACTIONS:
Interest received	$ 100	$ 57

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS:
Cash and cash equivalents	$ 11,309	$ 7,108
Restricted cash	7,122	7,775
Other current assets	465	415
TOTAL CURRENT ASSETS	18,896	15,298
NON-CURRENT ASSETS:
Property and equipment, net	121	134
Operating lease right-of-use assets	362	465
Restricted deposit	95	90
Funds in respect of employee rights upon retirement	6	6
TOTAL NON-CURRENT ASSETS	584	695
TOTAL ASSETS	19,480	15,993
CURRENT LIABILITIES:
Accounts payable	575	448
Accrued expenses and other payables	1,330	1,525
Current maturities of operating lease	199	230
TOTAL CURRENT LIABILITIES	2,104	2,203
NON-CURRENT LIABILITIES:
Operating lease liabilities	226	260
Other long-term liabilities	284	393
Liability for employee rights upon retirement	37	36
Pre-funded warrants liability	9,563	0
TOTAL NON-CURRENT LIABILITIES	10,110	689
TOTAL LIABILITIES	12,214	2,892
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary shares, NIS 0.0000769 par value: Authorized - as of June 30, 2026 and December 31, 2025, 140,010,000 shares; issued and outstanding as of June 30, 2026 and December 31, 2025, 49,290,233 and 45,452,167 shares, respectively	1	1
Additional paid-in capital	143,407	138,425
Accumulated other comprehensive income	41	41
Accumulated deficit	(136,183)	(125,366)
TOTAL SHAREHOLDERS' EQUITY	7,266	13,101
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 19,480	$ 15,993